When was Omass founded?

Omass was founded in 2016 and raised its 1st funding round within a year of its incorporation.

Where is Omass located?

Omass is headquartered in Oxford, United Kingdom. It is registered at Schrödinger Building Heatley Road, Oxford Science Park, Oxford, England, OX4 4GE.

Which legal entities is Omass associated with?

Omass is associated with OMass Therapeutics Limited.

How many employees does Omass have?

As of Dec 31, 2021, the latest employee count at Omass is 39.

Is Omass a funded company?

Omass is a funded company, having raised a total of $19.3M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jun 14, 2016.

How much is Omass worth?

The last known valuation of Omass was $***** as of Nov 26, 2018.

When was the latest funding round of Omass?

Omass' latest funding was a $***** Series A round on Nov 22, 2018, with participation from 2 investors. Its primary sector is Life Sciences Platforms and Tools. In United Kingdom, the Life Sciences Platforms and Tools sector has seen $98.8M in funding in 2026 to date.

What is the annual revenue of Omass?

Annual revenue of Omass is undefined as on Dec 31, 2020.

Where does Omass rank among its competitors?

Omass ranks 8th amongst 168 active competitors, of which 21 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was AFYREN, which secured $8.25M in Feb, 2026.

Who are the top competitors of Omass?

Omass' top competitors include AFYREN, Phylos Bioscience and Perfectus Biomed. Among them, AFYREN secured the most recent funding round in February, 2026.

Omass - 2026 Company Profile, Team, Funding, Competitors & Financials

Q: Is Omass an acquired company?

Omass got acquired by Syncona on Nov 26, 2018.

Company Details

Omass is a service offering organization involved in providing services using native mass spectrometry platform providing solutions in drug discovery. Oxford Mass Technologies (OMass) specializes in applying mass spectrometry to the characterization of intact protein assemblies, a technique often referred to as native mass spectrometry. It offers its services to pharmaceutical and research industries.

Website: omasstech.com
Social
Email ID: *****@omasstech.com
Registered Address: Schrödinger Building Heatley Road, Oxford Science Park, Oxford, England, OX4 4GE

Key Metrics

Founded Year

2016

Location

Oxford, United Kingdom

Stage

Acquired

Total Funding

$19.3M in 2 rounds

Latest Funding Round

Series A, Nov 22, 2018, $*****

Last Known Valuation

$***** as on Nov 26, 2018

Investors

Syncona & 1 more

Ranked

8^th among 168 active competitors

Annual Revenue

undefined as on Dec 31, 2020

Employee Count

39 as on Dec 31, 2021

Similar Companies

Trajan Scientific and Medical & 127 more

Exit Details

Acquired by Syncona (Nov 26, 2018)

View Omass' full profile

Omass is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
OMass Therapeutics Limited CIN: 10028228 , United Kingdom, Active	Feb 25, 2016	$0 (As on Dec 31, 2020)	28 (As on Dec 31, 2020)

Omass got acquired by Syncona on Nov 26, 2018 at an acquisition amount of $193M.

Click here to take a look at Omass's acquisition in detail

Omass has raised a total funding of $19.3M over 2 rounds. Its first funding round was on Jun 14, 2016. Its latest funding round was a Series A round on Nov 22, 2018 for $*****. 2 investors participated in its latest round. Omass has 2 institutional investors.

Here is the list of recent funding rounds of Omass:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 22, 2018	4512391	Series A	4878654	5114820	3943279	2666778
Jun 14, 2016	3265640	Seed	6624912	5706675	8109984	Oxford Science Enterprises

Access funding benchmarks and valuations. Sign up today!

View details of Omass's funding rounds and investors

The founders of Omass are Idlir Liko and Jonathan Hopper.

Here are the details of Omass' key team members:

Idlir Liko: Co-Founder & CTO of Omass and founder of 1 other company.
Jonathan Hopper: Co-Founder & Vice President of Omass.

View details of Omass's Founder profiles and Board Members

Omass' employee count trend

Omass has 39 employees as of Dec 21. The total employee count is 39.0% more than what it was in Dec 20. Here is Omass's employee count trend over the years:

Uncover Omass' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Omass include AFYREN, Phylos Bioscience and Perfectus Biomed. Here is the list of Top 10 competitors of Omass, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AFYREN 2012, Paris (France), Public	Provider of analytical services for microbiology, chemistry and bioprocesses industries	$132M	Kemin, Valquest Capital Management & 11 others	61/100
2nd	Phylos Bioscience 2014, Portland (United States), Series B	Developer of cannabis F1 hybrid seeds and natural THC products	$31.7M	Merida Capital Partners, Entourage Effect Capital ... & 6 others	60/100
3rd	Perfectus Biomed 2012, Daresbury (United Kingdom), Acquired	Provides services for research-based approach for microbiological testing	$765K	Future Planet Capital, Northern Powerhouse Investment Fund ... & 4 others	58/100
4th	Spore Biotechnologies 2022, Paris (France), Series A	Developer of microbial detection technology for life science industries	$35M	LocalGlobe, Singular & 13 others	53/100
5th	Trajan Scientific and Medical 2011, Ringwood East (Australia), Public	Specializing in automated sample preparation for chromatography and mass spectrometry applications	-	Gunnersen Investments	51/100
6th	NCIMB 1982, United Kingdom, Early Stage	Provider of biorepository, microbial culture collection and microbiology services	$2.27M	The Scottish National Investment Bank, Maven Capital Partners ... & 2 others	50/100
7th	Crawford Scientific 1985, Strathaven (United Kingdom), Acquired	Service provider in analytical testing	$9.78M	Maven Capital Partners, Clydesdale Bank	49/100
8th	Omass 2016, Oxford (United Kingdom), Acquired	Offers mass spectrometry related services	$19.3M	Syncona, Oxford Science Enterprises	48/100
9th	Clearbridge Health 2010, Singapore (Singapore), Public	Service provider of non-invasive urine, non-esoteric and esoteric testing, and tissues analysis	-	Asdew Acquisitions, Kolibra Capital & 3 others	47/100
10th	Steep Hill 2008, Berkeley (United States), Series A	Provider of cannabis testing and analytics services	$15.3M	Phyto Partners, Poseidon Asset Management ... & 4 others	46/100